Some other studies find blocking tumor-infiltrating macrophages with CSF1R inhibitor benefits the therapeutic effect of PD1 and CTLA4 antagonists [11], indicating tumor-associated macrophage (TAM) is a promising tumor therapy target. This evidence concerns the gene CSF1R and neoplasm.